C-FBRQAge Labs
epigenetic biomarkers, machine learning, diagnostics
measurementmeasuring
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FBRQ
C-FBRQC-FBRQepigenetic biomarkers, machine learning, diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Portfolio about portfolio team contact OSLO, Day , Time CEST Twitter (X), Linkedin, Instagram, ESG © xxxx Skyfall Ventures Our investments This is some text inside of a div block. grid list Pistachio is an information security SaaS focusd on social engineering. Pistachio is reinventing cyber security training, by among others, launching personalised attack simulations on employees in order to increase defensibility and reduce human cyber risk. Initial Investment: 2022 Status: close www Pistachio A SaaS to prevent human cyber risk info website Co-investors: Signals Venture Capital, J12 Ventur … rs Bakken & Bæck Initial Investment 2016 Exited 2019 website 2016 Naer A VR application for workshops Co-investors Startuplab Initial Investment 2022 website 2022 Smoc A B2B software company Co-investors Initial Investment 2020 website 2020 Joymo A hardware/software company Co-investors Investinor, Blommenholm, Startuplab Initial Investment 2018 website 2018 Capeesh A B2B language learning solution Co-investors Brighteye Venture, Tidligfasefondet Initial Investment 2019 w … act Step 1. ABOUT PORTFOLIO TEAM CONTACT Twitter (X), Linkedin, Instagram, ESG, Fund III © 2025 Skyfall Ventures
BioAge Labs sets 2026 shareholder votes, pay details | BIOA Proxy Statement --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stock … y incentive plan compensation earned for 2025 CEO 2025 option awards $1,941,390 Grant date fair value of options under 2015 and 2024 plans 2025 audit fees $845,000 Audit fees paid to KPMG LLP for fiscal year 2025 2024 audit fees $1,680,000 Audit fees paid to KPMG LLP for fiscal year 2024 Cormorant ownership 3,290,605 shares (7.41%) Common stock beneficially owned by Cormorant-affiliated entities Andreessen Horowitz ownership 3,233,170 shares (7.28%) Common stock beneficially … ment, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):   ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11     April 21, 2026 Dear Stockholder: You are cordially invited to attend the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of BioAge Labs, Inc. (the “Company") to be hel … Proxy Information 4 Corporate Governance Standards And Director Independence 6 Proposal No. 1 Election of Class II Directors 13 Proposal No. 2 Ratification of Independent Registered Public Accounting Firm 17 Report of the Audit Committee 18 Security Ownership of Certain Beneficial Owners and Management 19 Delinquent Section 16(A) Reports 20 Executive Officers 21 Executive Compensation 22 Certain Relationships and Related Party Transactions 26       BIOAGE LABS … ing firm will be obtained if the number of the votes cast “FOR” the proposal exceeds the number of votes cast “AGAINST” the proposal. A proxy submitted by a stockholder may indicate that the shares represented by the proxy are not being voted (stockholder withholding) with respect to a particular matter. In addition, a bro
Silicon Valley Global Network | Slowing aging technologically is a major effort among the elites.
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $39,142 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
%PDF-1.7 %���� 1 0 obj >/Metadata 17904 0 R/ViewerPreferences 17905 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Ymo7�n��� WD�3|�q� .w���P�������s�{���{��ʲ���H2�&�j�%93ϼ�������izz��=�������6�U�49���������ϯ���������ˋ�� ����������sup�R�g�[�Ae�j"e�6���l��ߩ���5� ���M^[�'u�i�*����E�0�� ��9�����=��J+�֛����ף�M�9��������y�G�Iј�;��N�����`��Isr��c� � B��0��;F���8v�5u ����~ mO���Uc���^��B�o�}�-��Cx� � ��R���u�+�t�a��
🗞️June News Round-Up🗞️ LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip to … Phase 2 trial of Alevatrix™ in bunionectomy patients, following its recent IND application. Infinity Bio, Inc. (MD, USA) closes an $8 million Series A funding round and acquires assets of immune profiling firm Serimmune. Kamari Pharma (Israel) announced closing of $23 Million Series A financing to advance its first-in-class oral TRPV3 inhibitor for rare genetic skin diseases Portal Biotech (England) raises $35M in Series A funding to commercialize world's first full-length s … Government & Research Grants MetasTx Inc (PA, USA) secures a $500,000 SBIR grant from the National Cancer Institute for developing a companion diagnostic test for prostate cancer. Tagomics (England) is awarded £860k from Innovate UK to develop a diagnostic test for early detection and treatment of colorectal cancer. Scope Biosciences B.V. (The Netherlands) secures €1 million in follow-on investment to scale its molecular diagnostics platform. Linear Diagnostics (England) … nsmitted infections. MicroPure Genomics Inc. (CA, USA) receives a $1.25 million grant from the National Science Foundation to continue its sample prep technology. Mitra bio (England) receives €2.5 million from European Innovation Council (EIC) Accelerator Nanostics Inc. (Canada) receives C$3.8 million grant to boost adoption of its ClarityDx prostate cancer risk tool. Pixelgen Technologies (Sweden) secures €12.5M in grant and equity funding from EIC Accelerator Single Technol … ity funding from EIC Accelerator Single Technologies (Sweden) secures €12.5M in grant and equity funding from EIC Accelerator UK Biobank receives £20 million from the UK government to support the Pharma Proteomics Project profiling the proteomes of 500,000 individuals. City of Hope (CA, USA) received $23.7 million from ARPA-H, to map biomarkers l
Portfolio about portfolio team contact OSLO, Day , Time CEST Twitter (X), Linkedin, Instagram, ESG © xxxx Skyfall Ventures Our investments This is some text inside of a div block. grid list Alva Technologies (now Hjemla.no) is a software company using machine intelligence to create a more transparent real estate market. Initial Investment: 2016 Status: Exited 2019 close www Alva A tool for property insights, including market values and sales data Exited 2019 info website Co-investors: Bakken & Bæck Naer is a workshop application for businesses utilizing virtual reality (VR) to enable eve … up-leveling remote work. Initial Investment: 2022 Status: close www Naer A VR application for workshops info website Co-investors: Startuplab Smoc.ai delivers a conversational marketing platform that reward user attention to increase user engagement, conversion,and loyalty. Initial Investment: 2020 Status: close www Smoc A B2B software company info website Co-investors: Joymo is a platform for grassroot sports organizations that want to broadcast and livestream games to a … any info website Co-investors: Age Labs is a molecular diagnostics company that apply machine intelligence on unique clinical data and biobank material to reduce the risk of developing drugs by accurately measuring biological age. Initial Investment: 2019 Status: close www Age Labs A bioinformatics company info website Co-investors: Aleap, Bakken & Bæck A digital infrastructure platform that let high quality brands easily publish and sell their products across several r … act Step 1. ABOUT PORTFOLIO TEAM CONTACT Twitter (X), Linkedin, Instagram, ESG, Fund III © 2025 Skyfall Ventures
Request for Startups in the Rejuvenation Biotechnology Space, 2019 Edition – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » Febru … ... Posted by: cuberat at February 25th, 2019 4:46 PM We need a venture capital fund dedicated to anti aging start ups. Posted by: Peter Christiansen at February 25th, 2019 4:55 PM @Peter Christiansen: There are several. Posted by: Reason at February 25th, 2019 5:13 PM @Reason, I wish to add a platform for creating medical nanorobots, even simplest form. This is a shame that we have no even one contemporary computer program for simulate MN. We have enough technology for worki … which is a much different risk management proposition Laura Deming's Longevity Fund is a drop in the bucket, at best considered a seed fund, and can do nothing more than "follow" other VC investors, throwing in a few $$ here and there into deals, but have no real impact on company direction And the new Longevity Vision Fund seems to be not much more than a pr campaign from In-Silico - they are even are stealing SoftBank "Vision Fund" name The field needs more real investors … bruary 26th, 2019 11:59 AM Please don't forget Methuselah Foundation/Methuselah Fund. We are founding investors/incubators of the following companies thanks to our donors and investors: Organovo (public) Matchgrid (acquired) Oisin (senolytics) OncoSenX (cancer indications using Oisin tech) Leucadia (Alzheimers) Volumetric (microvascularization via carbohydrate glass bio inks and hi res stereolithographic printer (revenue stage)) Turn Bio ( makes old cells young again - really … ly in our portfolio companies. We are considering options for doing a follow on fund, but haven't yet decided our go forward vehicle design. Posted by: David Gobel at February 27th, 2019 8:32 AM @BioInvest99 Also don't forget Kizoo Technology Ventures. @Jamie_NYC It's a shame, but the DRACO guys aren't responding anymore since ~2017 and their web
Age Care Labs completes acquisition of Epoch Elder Care - The HinduBusinessLine SENSEX 77,100.47 + 109.25 NIFTY 24,056.00 + 34.35 CRUDEOIL 6,809.00 + 140.00 GOLD 143,170.00 + 1,900.00 SILVER 220,600.00 + 7,525.00 SENSEX 77,100.47 + 109.25 NIFTY 24,056.00 + 34.35 NIFTY 24,056.00 + 34.35 CRUDEOIL 6,809.00 + 140.00 CRUDEOIL 6,809.00 + 140.00 GOLD 143,170.00 + 1,900.00 Subscribe Companies Markets Portfolio Opinion
Aleap - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Bank … ors : Europa , European Innovation Council and 4 Other s Latest Funding Round : Grant (prize money), Jul 07, 2023 , $ ***** Highlight : Acquired 5 . Hjemmelegene Key facts about Hjemmelegene Founded Year : 2017 Location : Oslo ( Norway ) Stage : Series A Total Funding till date : $7.88M Employee Count : 43 as on May 31, 2026 Investors : Kistefos , Schibsted Media Group and 2 Other s Latest Funding Round : Series A, Feb 14, 2022 , $ ***** View the full list of portfolio compan
Eurostars project: BioRADT – Precision Biomarkers for Personalized Treatment in Rheumatoid Arthritis - Lipum AB (publ) Press Releases Skip to content ABOUT US About us The story behind Lipum Management Team Board of Directors Scientific Advisory Board Code of Conduct (PDF – SE) RESEARCH & DEVELOPMENT Clinical development Phase 1 study SOL-116 (Completed) Eurostars project (Ongoing) Swelife project (Ongoing) Rheumatoid arthritis Medical need Other inflammatory diseases How a biologic drug is made Glossary MEDIA Press Releases (SE) Press Releases (EN) Presentations (SE) Presentations … l trials. With a total budget of approximately EUR 1.9 million, 50% of which is grant-funded, the three-year project will also contribute to the development of a companion diagnostic test, enabling targeted therapy and reducing unnecessary patient suffering. Age Labs, based in Oslo, specializes in epigenetic analysis and predictive algorithms for early disease detection. Initial studies on Lipum’s target molecule, BSSL, show promising potential to meet the project’s goals. Re
Age Labs (NO) - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 New Nvidia AI Su … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
BioAge CEO granted 330,000 stock options | BIOA Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … Inc. director and Chief Executive Officer Kristen Fortney reported receiving a grant of stock options on February 17, 2026. The award covers 330,000 options with direct ownership. The options vest in equal monthly installments over four years, starting February 1, 2026, as long as she continues serving the company. Positive None. Negative None. Insider Trade Summary 1 transaction reported Mixed 1 txn Insider Fortney Kristen Role Chief Executive Officer Type Security Shares P … r Fortney Kristen Role Chief Executive Officer Type Security Shares Price Value Grant/Award Stock Option (Right to Buy) 330,000 $0.00 -- Holdings After Transaction: Stock Option (Right to Buy) — 330,000 shares (Direct) Footnotes (1) [object Object] See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Form 4 Insider Transactions: What Each Field Means → Accepted by SEC EDGAR 02/19 … planation of Responses: 1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. /s/ Dov A. Goldstein as attorney-in-fact 02/19/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned … 4? BIOA reported that CEO and director Kristen Fortney acquired a stock option grant. The award covers 330,000 derivative securities described as a “Stock Option (Right to Buy),” reflecting an equity-based compensation grant rather than an open-market purchase or sale of common shares. How many stock options did BIOA CEO Kristen Fortney receive
BioAge Labs director receives 22,000 stock options | BIOA Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … Korean French Arabic BioAge Labs, Inc. director Michael H. Davidson received a grant of stock options covering 22,000 shares of common stock. These options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. Following this grant, Davidson holds 22,000 … ed 1 txn Insider Davidson Michael H. Role null Type Security Shares Price Value Grant/Award Stock Option (Right to Buy) 22,000 $0.00 -- Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null) Footnotes (1) [object Object] Key Figures Options granted: 22,000 options Exercise price: $15.48 per share Expiration date: June 9, 2036 +1 more 4 metrics Options granted 22,000 options Stock Option (Right to Buy) grant to director Exercise price $15. … Buy) grant to director Exercise price $15.48 per share Strike price for option grant Expiration date June 9, 2036 Option term end date Post-grant derivative holdings 22,000 options Total stock options following transaction Key Terms Stock Option (Right to Buy), exercise price, expiration date, vest, +1 more 5 terms Stock Option (Right to Buy) financial "security_title: "Stock Option (Right to Buy)"" exercise price financial "conversion_or_exercise_price: "15.4800 … expiration_date: "2036-06-09T00:00:00.000Z"" The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a co
Age Care Labs completes acquisition of Epoch Elder Care | Neha Sinha | 38 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s Use … Managing Principal, Lumis Partners, and the Lumis team for being the visionary fund you are. Exciting times ahead.. Like Reply 2 Reactions 3 Reactions Anubhav Agarwal 4y Report this comment Congrats neha! Like Reply 1 Reaction See more comments To view or add a comment, sign in 3,231 followers 125 Posts 6 Articles View Profile Follow More from this author Caring for Nanu Neha Sinha 1y Is residential care better than home care for dementia? Neha Sinha 3y How no
Age Labs Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Age Labs’ COVID-19 severity test being validated at Fürst, Norway’s largest medical laboratory August 8, 2022 Age Labs has developed a COVID-19 severity test (CST) that identifies patients at increased risk for fatal COVID-19 as early as 1 to 4 days after the first signs of disease. The CST is a blood-based test that employs a machine learning algorithm to find patients at increased risk. The algorithm identifies patterns in the immune system that are predictive of a severe disease course, and is able to classify
BioAge partners with Age Labs to decipher healthy longevity Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs team up to ... Xe … than 100,000 Northern European volunteers over more than 25 years of aging, and apply machine learning methods to the resultant data to reveal the key molecular mechanisms of healthy human longevity. The agreement grants BioAge exclusive access for the purpose of drug discovery to data generated by the partnership. “Biobanks containing samples collected from healthy people over decades of follow-up are exceptionally rare, and can provide invaluable insight into the molecular … longevity and bring substantial benefit to both companies.” Existing agreements grant BioAge access to other biobanks from multiple distinct geographical regions, collected from thousands of subjects with up to 45 years of follow-up after blood sampling. Biobank materials are coupled with health data including lifespan, disease status, and functional and cognitive outcomes. BioAge is actively seeking to expand the its human aging cohort data through additional biobank partner … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restoration chip MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity Ergothioneine: The little-known molecule tra
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Publications Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Publications , presentations and videos PAPERS Publications Riskedal, E. et al. Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood. Abstract #0531. Oral presentation at ACR Convergence (2022). Brunvoll, S. H. et al. Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial. In BMJ (p. e071245). BMJ (2
Product Pipeline Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Age Labs - a biomarker factory EPIPHANY EPIPHANY Age Labs has developed EPIPHANY, a proprietary machine learning-based biomarker discovery platform. Using EPIPHANY, we can measure the regulatory domains of 99% of the human genome. This allows us to create rich epigenetic profiles, quantifying gene activation both ahead of and in response to diseases and drug exposures, and develop biomarkers for early detection of diseases and drug response prediction. Pipeline Biomarker pipeline Our unique database of epi
Age Labs | Developing biomarkers for the early detection of age related diseases Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Developing biomarkers for early detection of age related diseases Welcome to Age Labs Meet our team Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for the early detection of age-related diseases. Our pipeline includes a groundbreaking test for early detection of rheumatoid arthritis, a cutting-edge biological age predictor and a test predicting the severity of COVID-19 infection, as we
Longevity Research Newsletter September 2022 | VitaDAO WHY LONGEVITY RESEARCH VITA LABS VITA TOKEN PROJECTS BLOG STORE GET VITA LOADING Back to the blog Reading Mode Dark Light SEPTEMBER 2022 14 min read Newsletters Longevity Research Newsletter September 2022 Welcome back to our monthly newsletter! This month we are excited to bring you an interview with Dr. Marco Demaria who has made some significant contributions to our understanding of cellular senescence. On this page Longevity Literature Hot Picks News Articles Funding Opportunities Job board Interview with Dr. Marco Demaria Outro Furthe … aging cells accumulate . Read more: https://bit.ly/3vVCTwd LongevityTech.fund II launches – now accepting new investors https://longevity.technology/news/longevitytech-fund-ii-launches-now-accepting-new-investors/ BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank https://www.businesswire.com/news/home/20220823005823/en/BioAge-Partners-With-Age-Labs-to-Decipher-Healthy-Longevity-Using-Samples-a … ic-clocks-predict-animals-true-biological-age-20220817/ As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked https://www.statnews.com/2022/08/09/anti-aging-projects-funding-much-discussed-trial-overlooked/ Martin O’Dea: longevity is burning bright in Ireland https://longevity.technology/news/martin-odea-longevity-is-burning-bright-in-ireland/ 40,000 pet dogs, one big question https://www.theatlantic.com/science/archive/2022/07/senior-dog-ag … Opportunities Life Extension Ventures https://www.lifex.vc/ A new $100 million fund that is focused on life extension for "people and planet." Job board Research Associate Position, Ochre Bio, New York, US Ochre Bio works on chronic liver health challenges, from reducing cirrhosis complications through metabolic stress, metabolism, and regeneration programs. https://jobs.lever.co/ochre-bio/c8da319b-f300-4945-9a1d-1cfc97fc9c29 Post-doc Position in Dr. Marco Demaria’s Lab - ER … rance are looking for a motivated postdoc with experience in proteomics. Please apply to [email protected] PhD Studentship in Dr. Ina Huppertz’s Lab - Max Planck Institute for Biology of Ageing, Cologne, Germany https://www.ageing-grad-school.de/phd/host-lab-proposals/dr-ina-huppertz Seeking a PhD student with a strong interest in RNA bio
#geroscience #precisionmedicine #longevity | Age Labs AS LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Poli
Contact us Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Contact Scam Warning We have just been made aware of a scam in which individuals are impersonating Age Labs employees on Telegram and offering fake job interviews. Age Labs does not use Telegram for recruitment and we currently have no open positions. Any messages claiming to represent Age Labs or its employees on Telegram are fraudulent. Please do not respond to such messages or share personal information. If you are unsure whether a communication is legitimate, contact us directly via our official website or
News Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Latest news and articles from Age Labs January 29, 2026 ⚠️ RECRUITMENT SCAM ALERT We have just been made aware of a scam in which individuals are impersonating Age Labs employees on Telegram and offering fake job interviews. Age Labs does not use Telegram for recruitment and we currently have no open positions. Any messages claiming to represent Age Labs or its employees on Telegram are fraudulent. Read Article December 9, 2025 PRADA - Advancing data-driven treatment selection in rheumatoid arthritis Read Article May
%PDF-1.7 %���� 20 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4�� ���A9�=�-� t�
Age Labs Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact ⚠️ RECRUITMENT SCAM ALERT January 29, 2026 We have just been made aware of a scam in which individuals are impersonating Age Labs employees on Telegram and offering fake job interviews. Age Labs does not use Telegram for recruitment and we currently have no open positions. Any messages claiming to represent Age Labs or its employees on Telegram are fraudulent. Please do not respond to such messages or share personal information. If you are unsure whether a communication is legitimate, contact us directly via our o
Mouse, an 8-month-old... - Animal Rescue League of Boston Facebook Log In Animal Rescue League of Boston's Post Animal Rescue League of Boston Verified account is asking for donations. December 29, 2025 · Shared with Public Mouse, an 8-month-old German Shepherd, recently arrived at ARL in a state of crisis. He is dangerously underweight and urgently needs your help. Because he is so thin, he requires a strict, medically supervised refeeding plan, specialized nutrition, months of medical treatment, and constant monitoring to help him gain weight safely so he can rebuild his strength. He ha
%PDF-1.5 %���� 857 0 obj > endobj xref 857 46 0000000016 00000 n 0000003424 00000 n 0000003526 00000 n 0000004087 00000 n 0000004234 00000 n 0000004740 00000 n 0000004777 00000 n 0000004891 00000 n 0000005372 00000 n 0000005646 00000 n 0000005673 00000 n 0000006558 00000 n 0000007162 00000 n 0000007669 00000 n 0000008209 00000 n 0000008742 00000 n 0000009277 00000 n 0000009773 00000 n 0000010599 00000 n 0000011338 00000 n 0000011610 00000 n 0000012072 00000 n 0000012626 00000 n 0000012663 00000 n 0000024529 00000 n 0000043907 00000 n 0000044738 00000 n 0000045026 00000 n 0000070278 00000 n 000 … 07C3242CD0C414 2015-03-17T16:06:29+02:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:CCC7580AC6CCE411BA15C41EDC724305 2015-03-17T18:52:47+02:00 Adobe Illustrator CS4 / saved xmp.iid:CDC7580AC6CCE411BA15C41EDC724305 2015-03-17T19:11:13+02:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:74117FEF20071168ACAFA0AD550E02D9 2015-03-18T11:58:39+02:0 … CCE411BA15C41EDC724305 xmp.did:24169F3620151168AE56E0D81BF97B5E 1 proof:pdf 712 application/postscript LOGO_GEO_5.indd Adobe PDF Library 9.0 False PDF/X-1:2001 PDF/X-1:2001 PDF/X-1a:2001 1 False False 204.999718 299.999948 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 endstream endobj 895 0 obj > endobj 896 0 obj > endobj 897 0 obj >/ExtGState >>>/Subtype/Form>>stream H��w6PH.V0C��� >stream CoverMagazine.EGNAzores2017.vEdit3 8 8 8 8 endstream endobj 899 0 obj … iPq3Eky8S6xt9mQVqvXMLNMSkSGBLK8rQ7FXYq7FXYq7FXYq7F
XYq7FXYq7FXYq7FXYq7FX//Z application/postscript 4 xmp.iid:92C2574AAA8DE4118AB3E80B6D6DD53F xmp.did:92C2574AAA8DE4118AB3E80B6D6DD53F xmp.did:758488FFB18DE4119383DCF72D51DDF4 created xmp.iid:758488FFB18DE4119383DCF72D51DDF4 2014-12-27T12:36:38+02:00 Adobe Photoshop CS4 (11.0x20080826 [20080826.m.456 2008/08/26:02:00:00 cutoff; m branch]) Windows converted from image/jpeg to image/tiff saved xmp.iid:768488FFB18DE4119383DCF72 … 07C3242CD0C414 2015-03-17T16:06:29+02:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:CCC7580AC6CCE411BA15C41EDC724305 2015-03-17T18:52:47+02:00 Adobe Illustrator CS4 / saved xmp.iid:CDC7580AC6CCE411BA15C41EDC724305 2015-03-17T19:11:13+02:00 Adobe Illustrator CS4 / converted from
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BioAge Labs opens shelf to register future securities | BIOA S-3 Registration --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Sto … Unless we state otherwise in the applicable prospectus supplement, pending the application of net proceeds, we expect to invest the net proceeds in investment-grade interest-bearing securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. 8   PLAN OF DIST RIBUTION We may sell the securities covered by this prospectus to one or more underwriters for public offering and sale by them, and may als … es under the Securities Act, and to reimburse them for certain expenses. We may grant underwriters who participate in the distribution of our securities under this prospectus an option to purchase additional securities in connection with the distribution. The securities we offer under this prospectus may or may not be listed through The Nasdaq Global Select Market or any other securities exchange. To facilitate the offering of securities, certain persons participating in the … f $7.74 per share. Common Stock Dividend rights Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. For more information about our dividend policy, see the section entitled & … d to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Right to receive liquidation distributions Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating pr
Royal Norwegian Consulate General in Houston Global Health Security Innovation Week 2022 Log in Join the event Language Organizing events? Resource center Contact app support Legal Home Agenda Speakers Exhibitors Royal Norwegian Consulate General in Houston Gold Sponsors Bookmark Information Norway has a rapidly growing health tech and life science ecosystem. This ecosystem is strongly supported by academic and research institutions, government organizations, and four industry clusters. Incubators are also present in most university cities to support entrepreneurship and new industry groups. T
BioAge Labs | Vacancy About us Platform Pipeline Overview NLRP3 Apelin / APJ Resources Publications Podcast Careers Investors Loading description... Job Type Description APPLY FOR THIS POSITION Address 5885 Hollis Street, Suite 370 Emeryville, CA 94608 General [email protected] (510) 806-1445 Media [email protected] Partnering [email protected] © Copyright 2020-2026. All Rights Reserved Privacy Address 5885 Hollis Street, Suite 370 Emeryville, CA 94608 General [email protected] (510) 806-1445 Media [email protected] Partnering [email protected] © Copyright 2
Cenna Biosciences Selected for NIH Support at BIO Convention | Nazneen Dewji, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … uture of the Baltimore biotech ecosystem. These funds from the Build Our Future Grant will be used to scale the CLIA Catalyst program at our recently opened incubator, Blackbird BioHub. CLIA Catalyst is a shared CLIA laboratory platform conceived and implemented by Eric Van Gieson , Neil "Herm" Hermansen , and colleagues at EPOCH Epigenetics, one of Blackbird BioHub’s anchor residents. The CLIA Catalyst Facility is designed to serve as a critical bridge for emerging Maryland … al testing, significantly shortening the time to deploy a diagnostic test. This award reflects a shared commitment to accelerating technologies and strengthening Baltimore’s position as a growing biotech hub. We’re thankful to have the Maryland Department of Commerce and EPOCH Epigenetics as partners in building infrastructure that helps translate breakthrough science into patient impact faster. https://lnkd.in/eE7ig4vU https://lnkd.in/eXmSUjtq 110 4 Comments Like Comment Sha … ndings at Probiota Americas and accepted the Scientific Frontiers 2026 Industry award on behalf of AG1 and our internal team of scientists Erick W., Ralph Esposito ND, LAc Jeremy Townsend PhD for this research. This award recognizes our research advancing probiotic cell counting with digital PCR (dPCR), a DNA-based method that ensures we're able to measure probiotic potency with greater precision than ever before. This work was made possible through partnership with two indus … ndings at Probiota Americas and accepted the Scientific Frontiers 2026 Industry award on behalf of AG1 and our internal team of scientists Erick W., Ralph Esposito ND, LAc Jeremy Townsend PhD for this research. This award recognizes our research advancing probiotic cell counting with digital PCR (dPCR), a DNA-based method that ensures we're able
BioAge Labs | Targeting metabolic aging About us Platform Pipeline Overview NLRP3 Apelin / APJ Resources Publications Podcast Careers Investors We are harnessing the biology of human aging to develop new therapies for metabolic diseases We are harnessing the biology of human aging to develop new therapies for metabolic diseases We are harnessing the biology of human aging to develop new therapies for metabolic diseases Find out more Harnessing aging to transform health Obesity and other metabolic diseases are among the most prevalent and pressing health challenges of our time. Age is a critica
BioAge Labs | Careers About us Platform Pipeline Overview NLRP3 Apelin / APJ Resources Publications Podcast Careers Investors Join us in our mission BioAge is committed to discovering new drugs for metabolic disease through the lens of aging biology — improving wellness throughout the lifespan and helping people enjoy longer, healthier lives. We are always seeking talented individuals who share our passion to join us in our mission. Perks and benefits In addition to competitive compensation, we offer: A flexible, remote-first culture Comprehensive health and wellness benefits (health, dental,
C2E2 Official Group | There was an exhibitor that was selling artworks andnT-shirts of whales & jellyfish made out of equations
30 Aging Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Aging 30 Employers in 32 locations Employers working on Aging work in 25 other areas Displaying 1 - 15 of 25 related areas Show: 15 50 All Cell and Gene Therapy (6) Therapeutics (5) Regenerative Medicine (4) Artificial Intelligence (3) Diagnostics (3) Alzheimer's (2) Epigeneti
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Nearly half of diabetic patients in the US never get their annual diabetic eye exam. Not because they don't want to, but because it means a separate referral, a separate specialist, and an… | Oivi LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in yo
--> NEW AGE Laboratories | Plant Sap Analysis top of page Agriculture Plant Sap Analysis Agricultural Water Soil Fertigation, Compost, and Soil Amendment Virus & Viroid Testing Plant Tissue Testing Livestock Feed Sustainable Agriculture Food Safety Microbiology Food Safety - Water Pesticides Nutrient Analysis Finished Product Testing Why Outsource? Environmental Forms & Guides More Publications & Media Shipping Distributors & Consultants Workshops About Us Contact Us "Science You Can Use, Partners You Can Trust" Agriculture Food Safety Environmental About Plant Sap An
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BioAge Labs, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 26 Mar 2026 BioAge Labs, Inc. Startups | Public Company | 2015 | California, United States | 50-100 | NASDAQ: BIOA | bioagelabs.com Startups | Public Company | 2015 | California, United States | 50-100 | NASDAQ: BIOA | bioagelabs.com Last update 26 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Endocrinology and Metabolic Disease Nervous System Diseases Small molecul … olio of orally active APJ agonists for which it filed a U.S. provisional patent application in May 2025. BioAge intends to first IND for an APJ program by 2026 year end. Upsized follow-on public offering In January 2026, BioAge completed an upsized follow-on public offering of 5,897,435 shares of common stock at a public offering price of $19.50 per share, generating gross proceeds of approximately $115.0 million. In February 2026, the underwriters exercised their overallotme … lents, and marketable securities as of December 31, 2025, will be sufficient to fund operations through 2029 based on its current operating plan. Strategic partnerships and discovery platform BioAge's multi-year research collaboration with Novartis, focused on discovering novel therapeutic targets at the intersection of aging biology and exercise physiology, continued to advance, with multiple targets under evaluation. The Company progressed its strategic collaboration with L … BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk a … million purchase of Ventyx stock in 2024. Four days later, Lilly made its first proposal at $12.50 per share in cash. Ventyx’s board wanted more and considered the initial proposal “insufficient.” Such reply is relatively standard in biopharma M&A deal discussions. It was coming up on the holidays, and Ventyx wanted to know whether Sanofi and Par
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Age Labs AS Revenue, Valuation & Funding History (2025) 00 d : 00 h : 00 m : 00 s AI Growth Summit: 9 Tactics to Add $10m Fast | June 30 121/150 seats taken Save Your Seat Home SaaS Database Add Your Company Podcast Pricing Sections Company Revenue Valuation and Funding Founder and CEO Employees and Team Size FAQ Contacts Competitors SaaS Database / Industries / Age Labs AS Age Labs AS Oslo , Oslo , Norway agelabs.com Valuation $10.4M 2025 Revenue $3.5M (Est.) Funding $0 Team 25 Founded 2017 Company Revenue Valuation and Funding Founder and CEO Employees and Team Size FAQ Contacts Competit
Sparket Zwipe-sjef har fått ny jobb i «biomarkørfabrikk» støttet av Startuplab og Skyfall Jump to main content Shifter + Nyhetsbrev Annonsere Jobb Event Abonner Logg inn Søk Shifter + Annonsere Nyhetsbrev Jobb Podcast Investordatabasen Emisjonsdatabasen Event La denne stå tom Om Shifter Cookie Personvern Logg inn Min side Logg ut Annonse karriere Sparket Zwipe-sjef har fått ny jobb i «biomarkørfabrikk» støttet av Startuplab og Skyfall André Løvestam har tatt på seg sjefsjobben i Age Labs. André Løvestam, daglig leder i Age Labs Jörgen Skjelsbæk Joakim Birkeli Jacobsen Joakim Birkeli Jacobsen J
Central PA Yoga/Wellness Community Events | Screeeeeenshot!!!! Our guest speakers and workshops have been thoughtfully placed throughout the day, and we offer them as a courtesy for all of the i...
BioAge Labs Reports Full Year 2025 Financial Results and --> Accessibility: Skip TopNav BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 March 24, 2026 09:00 ET | Source: BioAge Labs, Inc. BioAge Labs, Inc. Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansi … olio of orally active APJ agonists for which it filed a U.S. provisional patent application in May 2025. BioAge intends to file the first IND for an APJ program by 2026 year end. Upsized follow-on public offering In January 2026, BioAge completed an upsized follow-on public offering of 5,897,435 shares of common stock at a public offering price of $19.50 per share, generating gross proceeds of approximately $115.0 million. In February 2026, the underwriters exercised their ov … lents, and marketable securities as of December 31, 2025, will be sufficient to fund operations through 2029 based on its current operating plan. Strategic partnerships and discovery platform BioAge's multi-year research collaboration with Novartis, focused on discovering novel therapeutic targets at the intersection of aging biology and exercise physiology, continued to advance, with multiple targets under evaluation. The Company progressed its strategic collaboration with L … BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk a
BioAge Labs details 2025 results and cash runway | BIOA Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stoc … d $2.0M outstanding under its term loan. Management believes this liquidity can fund planned operations through 2029 while advancing BGE-102 into Phase 2a cardiometabolic and ophthalmology trials and preparing APJ agonist INDs. Positive None. Negative None. Insights Biotech equity analyst neutral BioAge is well-funded to advance multiple metabolic-disease programs, but remains pre-revenue and loss-making. BioAge Labs shifted meaningfully into a multi-asset development phase i … written offering completed in early 2026. Management estimates this capital can fund operations through 2029, giving time to read out full Phase 1 data for BGE-102 in the first half of 2026 and initiate two proof-of-concept trials plus initial APJ INDs. Actual outcomes will depend on clinical data quality, regulatory feedback and the pace of pipeline expansion, which together drive future funding needs and potential partnering decisions. See more from StockTitan in Google Sea … eding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … gies, 3   measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan.   The BioAge platform encompasses over 150 million molecular data points spanning over 25 thousand individual participant profiles and over 50 years of fo
AGE LABS AS | Norway Health Tech Skip to main content Members Members Projects and services Projects and services News and Events News and Events About us About us no | en Søk Search Logg inn Login Become a member Meny Meny Lukk Members AGE LABS AS Website Explore the opportunities that await in Norway Health Tech – Norway’s largest ecosystem for health technology. Become a member Membership Sign up for our newsletter! Stay up to date with what's happening in the health cluster through our newsletter. We send regular updates with the latest news on innovation, member successes, funding op
The Hub | Age Labs Find jobs Browse startups Pricing Scout For startups Sign up Log in Age Labs Age Labs is a Norwegian molecular diagnostics company that discovers, develops and commercializes biomarkers for the early detection of age-related diseases. We offer a service for evaluating epigenetic drug effects for use in clinical trials. Our biomarker discovery pipeline includes a biological age predictor and a test predicting the severity of COVID-19 infection. To date, we have raised 30 MNOK in private and public funding, and became a Nordic Startup Awards finalist in 2020. We are supported
Epigenetics and Aging - Skip to content News & Views ShareLab Team Bio-entrepreneurs Service providers Partners Visit us Site Search Search for: Search News 23. september 202223. september 2022 by Esben A. Nilssen Kalleberg and Age Labs - Epigenetics and how to age like a fine wine A Canary in a Coal Mine By Johanne Kloster Ellingsen , published 23 September, 2022 “I do things I’m interested in”, Karl Trygve explains, referring to his diverse, and impressive, resume. His most recent endeavour is using the combined power of biobanks and machine learning to help people stay healthier longer … moving the world in the right direction. “The work needs to be meaningful, have application value, and solve a problem for someone”. _________________ About Age Labs AS Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for the early detection of age-related diseases. The pipeline includes a test for early detection of rheumatoid arthritis, a biological age predictor and a test predicting the severity of COVID-19 infectio
Karl Trygve Kalleberg - CSO And Co-founder at Age Labs AS | The Org Platform Enrich Pricing Log in Sign up Age Labs AS Karl Trygve Kalleberg Unverified Karl Trygve Kalleberg CSO And Co-founder Contact Karl Trygve Kalleberg has a diverse work experience in sectors such as technology, investment, and healthcare. Karl Trygve is currently the CEO and Co-founder of Age Labs AS since October 2020, after serving as the CTO and Co-founder of the same company from 2017 to 2020. Prior to that, they were a Technology Advisor and Co-founder of Sensonomic, a company focused on translating complex data ab
Looking forward to doing some great science with Karl Trygve Kalleberg and Arne Søraas at Age Labs AS that will move the field forward. | Eric Morgen LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn B
Our Team at Age Labs Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact We are a team of scientists, engineers , and MDs . We have founded several successful companies, and have a deep understanding in aging, genetics and predictive analytics. We collaborate closely with world-leading experts on building prediction algorithms based on epigenetics and DNA methylation measurement techniques and have gathered an interdisciplinary team of accomplished researchers and developers - both in the company Age Labs and among our collaborators from the private and public sector. MANAG … the the King’s Gold Medal for his Ph.D., as well as a EULAR Young Investigator Award in 2009. Since then Espen has focused on treatment of rheumatic diseases, and initiated several large multicenter studies investigating novel treatment strategies. Siri Lillegraven MD PhD Deputy Director of Remedy, Consultant Rheumatologist Siri is the deputy director of REMEDY (Center for treatment of Rheumatic and Musculoskeletal Diseases), a senior researcher and Unitlead for Clinical Re
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
The New Future of the Profession: 'Longevity Advisors' Tax Facts Luminaries Podcasts Videos Webcasts Resource Center Bookstore Thought Leaders Tax Facts Luminaries Awards Newsletters Join PRO Now Industry Spotlight Portfolio Retirement Planning Financial Planning Practice Management Regulation and Compliance Technology Annuities & Insurance PRO Sign In Register Now Join Pro Now Newsletter Tax Facts Search PRO Industry Spotlight Portfolio Retirement Planning Financial Planning Practice Management Regulation and Compliance Technology Annuities & Insurance MORE TO EXPLORE Tax Fa … ghts Reserved. Request academic re-use from www.copyright.com . All other uses, submit a request to [email protected] . For more information visit Asset & Logo Licensing. Immediate Answers to Critical Tax Questions At Your Fingertips Keep up with the latest tax rules and regulations with weekly, exclusive updates by our Tax Facts experts. Get More Information Recently Added Q&As Recently Updated Q&As What is the temporary “senior deduction” deduction for taxp
BioAge plans $75M common stock offering | BIOA Prospectus Summary --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga … table securities, and currently expects existing cash plus offering proceeds to fund operations and capital needs through 2029. Net proceeds are intended mainly for research, clinical and manufacturing activities for BGE-102 and the NLRP3 and APJ programs, as well as working capital and general corporate purposes. Positive None. Negative None. Insights Biopharma equity & capital structure analyst neutral $75M equity raise extends cash runway but adds dilution. BioAge plan … peline. The company states that existing cash plus net proceeds are expected to fund operating expenses and capital expenditures through 2029. Proceeds are earmarked for research, clinical and process development and manufacturing of BGE‑102 and the broader NLRP3 and APJ programs, alongside working capital, capital spending, repayment of indebtedness and other general corporate purposes. The document also notes immediate and substantial dilution to new investors relative to t … ncorporated by reference, gives more general information, some of which may not apply to this offering. Generally, when we refer only to the “prospectus,” we are referring to both parts combined. This prospectus supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. If information in this prospectus supplement is inconsistent with … adoption of certain accounting standards until those standards would otherwise apply to private companies. Any decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. We have elected to use this extended transition period. S-3 Table of Contents We will cease to be an eme
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Age Labs | Developing biomarkers for the early detection of age related diseases Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Developing biomarkers for early detection of age related diseases Welcome to Age Labs Meet our team Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for the early detection of age-related diseases. Our pipeline includes a groundbreaking test for early detection of rheumatoid arthritis, a cutting-edge biological age predictor and a test predicting the severity of COVID-19 infection, as we
PK Model in Pediatric Patients: Assessing the Impact of a Multivariate Correlated Distribution of Covariates on PK Exposures PK Model in Pediatric Patients: Assessing the Impact of a Multivariate Correlated Distribution of Covariates on PK Exposures Specifying A Pediatric Simulation Model PK Parameters and Associated BSV ranges Simulating Age/Weight Pairs Using NHANES LMS Values Simulation with the Multivariate Realistic Distribution PK Parameters Summaries and Distribution Plots A Forest Plot with a Side Table In this vignette we illustrate how to simulate joint effects of covariates in a ped
Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood - ACR Meeting Abstracts ACR Meeting Abstracts Meetings 2026 ACR/ARP PRSYM ACR Convergence 2025 ACR Convergence 2024 ACR Convergence 2023 2023 ACR/ARP PRSYM ACR Convergence 2022 ACR Convergence 2021 2020-2009 Meetings Download Abstracts Keyword Index Advanced Search Your Favorites Favorites Login View and print all favorites Clear all your favorites ACR Meetings Abstract Number: 0531 Development and Performance of a Diagnostic Precision Biomarker for Seronegati
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 4 0 obj > stream x���|TW�?������}[�R T��� �5��σ?���=Hjr�k�S�� ��/�@�%߹ nx#�"y��6`� m ��0���E��0s��"?:Y� ?�l%������ �'�_|��h����,e w!�A�{A�+�❾(�9'k]���b�Q�7�, �Q�/�jlR0r�l��;ɳg�^,JBF�ا�P �"�5�w�&��� `>I�Ƅ��۲?���A���n�Hr���btz��Q�S0�ΖҤ@���.B�7���ׯ�Nm �A��Mn���uDW�#��(�[�v��y�Ś��B�Y�����] Ԩ��B>�?z��NXV���5 JŐ�/l�/�E� �?ڒ��ȑC�BZ���7�>ز���P^C����?�;2R^��~>�l)�,o�[i�����A���팘��Hx[qC�k�������w+����-��#;s6�z �������1|��/ �k��%��#�O ��-�0�[��߽���Y��r��4%�o$��t~�rx�n�S�F��� �%�r��̃��1Ϯ�V#$���:~�^b�oy0�|j��[#�'�
Global Supply Chain Trucking And Distribution | CourseVector Skip to content 717-516-6955 [email protected] Hosting • Web • Marketing Home Services Website Design Website Design Portfolio Web Design Quote Request Website Accessibility Made Easy (ADA) Hosting Hosting Worksheet Email Services Tech Updates & Fixes Update Plans SEO Services SEO Services FREE SEO Analysis Request Marketing Quote Request Additional Services Training for WordPress Custom Programming Logo Design Emergency Alert System Credit Card Services for Small Business & Non-Profits Programs Reseller Partnership Pr
Biological Age Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact Advanced measurement of biological age Although chronological aging is universal, biological age can vary considerably between individuals. This variation is shaped by numerous factors, including environmental influences, lifestyle choices, and genetic makeup. Gaining insight into one's personal cellular aging process is a crucial step towards taking well-informed, proactive measures to optimize that process. Age Labs provides a service for sophisticated measurement of epigenetic biological age and heal
Age Labs Plans To Predict Disease Risk And Mortality Using Datasets From Norwegian Biobanks - Biobanking.com Linkedin RSS X Sign in Home News & Articles News Stories Industry News Research News Insights & Opinions Expert Contributions Industry Insights Interviews Biobank Spotlight Top-Lists Topics Products & Innovations Cryopreservation Data & Informatics Automation New Biobanks AI & Blockchain Ethical, Legal & Social Issues Sample Management Cell Banking Tissue & Organ Banking Blood & Biofluids Banking DNA/RNA Banking Animal Biobanking Plant Biobanking Microbi
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates August 7, 2025 | 10 min read Twitter LinkedIn Facebook Email Print Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agre … ion across all indications. In May 2025, BioAge filed a U.S. provisional patent application for a new class of orally active, chemically distinct APJ agonists with picomolar potency and drug-like properties including high solubility and metabolic stability. Discovery platform expansion In June 2025, BioAge announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway through its collaboration with Age Labs AS. BioAge will … xisting cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank August 24, 2022 | 4 min read Twitter LinkedIn Facebook Email Print BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes … than 100,000 Northern European volunteers over more than 25 years of aging, and apply machine learning methods to the resultant data to reveal the key molecular mechanisms of healthy human longevity. The agreement grants the Company exclusive access for the purpose of drug discovery to data generated by the partnership. “Biobanks containing samples collected from healthy people over decades of follow-up are exceptionally rare, and can provide invaluable insight into the molec … longevity and bring substantial benefit to both companies.” Existing agreements grant BioAge access to other biobanks from multiple distinct geographical regions, collected from thousands of subjects with up to 45 years of follow-up after blood sampling. Biobank materials are coupled with health data including lifespan, disease status, and functional and cognitive outcomes. BioAge is actively seeking to expand the Company’s human aging cohort data through additional biobank p … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Age Labs awarded €1 million in R&D funding from the Research Council of Norway - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Age Labs awarded €1 million in R&D funding from the Research Council of Norway February 4, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Age Labs is developing a precise novel biomarker that will measure biological aging, by utilising extensive and unique datasets from Norwegian biobanks combined with mach … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Age Labs Partners With the Norwegian Institute of Public Health and Two Hospitals to Develop a Novel COVID-19 Test Assessing the Risk of Severe Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development F … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Age Labs Partners With the Norwegian Institute of Public Health and Two Hospitals to Develop a Novel COVID-19 Test Assessing the Risk of Severe Disease July 16, 2020 | 2 min read Twitter LinkedIn Facebook Email Print The test will identify high-risk individuals and enable earlier and targeted … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioAge partners with Age Labs to study healthy life length Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by … than 100,000 northern European volunteers over more than 25 years of aging, and apply machine learning methods to the data to reveal molecular mechanisms of healthy human longevity. The agreement grants the company exclusive access for the purpose of drug discovery to data generated by the partnership. “Biobanks containing samples collected from healthy people over decades of follow-up are exceptionally rare, and can provide invaluable insight into the molecular bases of heal … benefit to both companies.” Expanding biobank partnerships Existing agreements grant BioAge access to other biobanks from multiple distinct geographical regions, collected from thousands of subjects with up to 45 years of follow-up after blood sampling. Biobank materials are coupled with health data including lifespan, disease status, and functional and cognitive outcomes. BioAge is seeking to expand the company’s human aging cohort data through additional biobank partnershi … harm adds to oncology pipeline National Hemophilia Foundation launches research fund Sherlock obtains Cas12 CRISPR patent Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies Latest Articles De-risking neurology drug development with better mouse models Roche, a company built on oncology and diagnostics reinventing its pipeline Bronchiectasis treatment after brensocatib
About Team BIOMARKERS Services BiologiCAL AGE Publications News ABOUT Contact About us Age Labs AS is a Norwegian life science company founded in 2017. Our primary aim is the discovery of clinically relevant biomarkers for early detection of age-related diseases. We focus on analyzing epigenetic changes in immune cells and build predictive algorithms to identify biomarkers of early disease detection and assess disease risk. Founded by a team of scientists, medical doctors, and engineers, the company possesses a deep understanding of aging, genetics, and analytics needed for successful growth.